

Anti-CD38 Antibody (Mezagitamab)

Introduction

Mezagitamab (TAK-079) is an IgG1 λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement-dependent cytotoxicity. Mezagitamab has potential applications in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP).

Product parameters

Alternative Names	TAK 079, TAK-079
Target Accession	P28907
Target	CD38
CAS number	2227490-52-8
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human CD38 NHis at 2 ug/mL can bind Anti-CD38 Antibody (Mezagitamab), EC50=0.0275 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

